Management strategy for rectal cancer patients with complete clinical response after chemoradiotherapy
https://doi.org/10.21294/1814-4861-2025-24-1-110-114
Abstract
The aim of the study was to analyze the immediate and long-term treatment outcomes in rectal cancer patients with complete clinical response to chemoradiotherapy. Material and methods. The results of chemoradiotherapy were analyzed in 20 patients with cancer of the middle and lower ampullary rectum, who were treated at the Irkutsk Regional Cancer Center from 2018 to 2022. The median age of the patients was 68.4 ± 2.3 years. There were 60 % men and 40 % women. The tumor was located in the lower and middle parts of the rectum in 85 % and 15 % of the patients, respectively. The size of the tumor was 3.7 ± 0.4 cm. Results. During a median 30-month follow-up (24–60 months), 4 patients experienced local recurrence and 1 patient had lung metastases confirmed by thoracoscopic biopsy. The 2-year overall and disease-free survival rates were 100 % and 75 %, respectively. Conclusion. The strategy of an active surveillance for rectal cancer patients who have achieved complete clinical response after chemoradiotherapy is safe and leads to non-inferior overall and relapse-free survival compared to standard surgery. This treatment option helps to avoid postoperative complications, thereby improving patients’ quality of life.
About the Authors
A. A. Medvednikov
Irkutsk State Medical University of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education – Branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of Russia; Regional Cancer Center
Russian Federation
Russian Federation
Andrey A. Medvednikov - MD, Assistant, Department of Oncology and Radiation Therapy, Irkutsk State Medical University of the Ministry of Health of Russia; Assistant, Department of Oncology, Russian Medical Academy of Continuous Professional Education – branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of Russia; Head of the Department of Abdominal Oncology No. 3, Regional Cancer Center.
1, Krasnogo Vosstaniya St., Irkutsk, 664003; 2/1, build. 1, Barrikadnaya St., Moscow, 125993; 32, Frunze St., Irkutsk, 664044
S. I. Radostev
Irkutsk State Medical University of the Ministry of Health of Russia; Regional Cancer Center
Russian Federation
Russian Federation
Sergey I. Radostev - MD, Assistant, Department of Faculty Surgery and Urology, Irkutsk State Medical University of the Ministry of Health of Russia; Surgeon, Regional Cancer Center.
1, Krasnogo Vosstaniya St., Irkutsk, 664003; 32, Frunze St., Irkutsk, 664044
A. V. Shelekhov
Irkutsk State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Alexey V. Shelehov - MD, DSc, Head of the Department of Oncology and Radiation Therapy, Irkutsk State Medical University of the Ministry of Health of Russia.
1, Krasnogo Vosstaniya St., Irkutsk, 664003
R. A. Zubkov
Irkutsk State Medical University of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education – Branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of Russia; Regional Cancer Center
Russian Federation
Russian Federation
Roman A. Zubkov - MD, Assistant, Department of Oncology and Radiation Therapy, Irkutsk State Medical University of the Ministry of Health of Russia; Assistant, Department of Oncology, Russian Medical Academy of Continuous Professional Education – branch of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of Russia; Chief Physician, Regional Cancer Center.
1, Krasnogo Vosstaniya St., Irkutsk, 664003; 2/1, build. 1, Barrikadnaya St., Moscow, 125993; 32, Frunze St., Irkutsk, 664044
References
1. Clinical guidelines. Rectal cancer. 2022. 111 p. (in Russian).
2. Abrosimov A.Iu., Berdov B.A., Erygin D.V., Kondrashova L.M., Lushnikov E.F., Nevolskikh A.A. Pathomorphism of rectal cancer during neoadjuvant chemoradiotherapy. Russian Journal of Archive of Pathology. 2013; 75(6): 27–31. (in Russian). EDN: RSVZIZ.
3. Dvornichenko V.V., Afanasiev S.G., Shelekhov A.V., Moskvina N.A. Radiotherapy in the combined modality treatment for rectal cancer: The review of the literature V. Siberian Journal of Oncology. 2009; 1: 72–77. (in Russian). EDN: KNWYPF.
4. Erygin D.V., Berdov B.A., Nevolskikh A.A., Titova L.N., Smirnova S.G. Neoadjuvant chemoradiotherapy for locally advanced rectal cancer. P.A. Herzen Journal of Oncology. 2015; 4(1): 13–20. (in Russian). doi: 10.17116/onkolog20154113-20. EDN: TYOPBL.
5. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., Gusareva M.A., Kharagezov D.A., Milakin A.G., Ilchenko S.A. Complete clinical response of rectal cancer to chemoradiotherapy: tactics. Problems in Oncology. 2017; 63(6): 838–42. (in Russian). doi: 10.37469/0507-3758-2017-63-6-838-842. EDN: ZXWFEF.
6. Kuzmichev D.V., Mamedli Z.Z., Polynovskiy A.V., Madyarov Zh.M., Tkachev S.I., Aniskin A.A. Neoadjuvant chemotherapy in the combination treatment for locally advanced rectal cancer: currently available options. Colorectal Oncology. 2018; 8(3): 36–41. (in Russian). doi: 10.17650/2220-3478-2018-8-3-36-41. EDN: YMBMFN.
7. Afanasyev S.G., Dobrodeyev A.Yu., Avgustinovich A.V., Tarasova A.S., Volkov M.Yu., Urmonov U.B., Dimcha A.A., Startseva J.A., Plakseeva D.A., Usova A.V., Spirina L.V. Organ saving treatment of low rectal cancer. Problems in Oncology. 2019; 65(6): 850–854. (in Russian). EDN: RVLEIH.
8. Dudaev Z.A., Khudoerov Dzh.Kh., Mamedli Z.Z., Aliev V.A., Gordeev S.S., Myshlyakov V.S. “Watch and wait” strategy (active dynamic follow-up) in the management of rectal cancer patients with a complete clinical response. Pelvic Surgery and Oncology. 2022; 12(1): 35–40. (in Russian). doi: 10.17650/2686-9594-2022-12-1-35-40. EDN: AHASIX.
9. Fedyanin M.Yu., Elsunkaeva Kh.Kh.M., Pokataev I.A., Tryakin A.A., Bulanov A.A., Sekhina O.V., Chekini D.A., Ignatova E.O., Gordeev S.S., Aliev V.A., Kuzmichev D.V., Mamedli Z.Z., Chernykh M.V., Glebovskaya V.V., Tkachev S.I., Kozlov N.A., Tjulandin S.A. Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study. Colorectal oncology. 2018; 8(2): 24–37. (in Russian). doi: 10.17650/2220-3478-2018-8-2-24-37. EDN: OVIFRJ.
Review
For citations:
Medvednikov A.A., Radostev S.I., Shelekhov A.V., Zubkov R.A. Management strategy for rectal cancer patients with complete clinical response after chemoradiotherapy. Siberian journal of oncology. 2025;24(1):110-114. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-1-110-114
Views:
844
Email this article 
